

Activin Receptor Type IIA antibody [C1C3]

Cat. No. GTX114053

Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Applications	WB
Reactivity	Human

Package
100 µl, 25 µl

Applications

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
WB	1:5000-1:20000

Not tested in other applications.

Calculated MW 58 kDa. ([Note](#))

Product Note Based on sequence homology, this antibody may cross react with Activin Receptor Type IIB protein. This antibody was raised against human Activin A Receptor type IIA Intracellular domain.

Properties

Form	Liquid
Buffer	PBS, 20% Glycerol
Preservative	0.025% ProClin 300
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
Concentration	1 mg/ml (Please refer to the vial label for the specific concentration.)
Immunogen	Recombinant protein encompassing a sequence within the Intracellular domain of human Activin A Receptor type IIA. The exact sequence is proprietary.
Purification	Purified by antigen-affinity chromatography.
Conjugation	Unconjugated

Note

For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.


Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.



For full product information, images and publications, please visit our [website](#).

Date 2026 / 10 / 10 Page 1 of 2

DATA IMAGES



GTX114053 WB Image

Activin A Receptor type IIA antibody detects Activin A Receptor type IIA protein by Western blot analysis. Whole cell extracts (30 µg) was separated by 10% SDS-PAGE, and the membrane was blotted with Activin A Receptor type IIA antibody (GTX114053) diluted by 1:4000.



For full product information, images and publications, please visit our [website](#).